The pandemic has disrupted and affected so much of daily life since the start of 2020. One of those ways has been many women’s inability to meet in person with providers to receive treatment for postpartum symptoms dealing with pelvic health. This inability to receive care was one of the driving forces behind the MUTU Clinical Trial.

In early 2020 the Lead Specialist for the Pelvic and Maternal Health Physiotherapy Team at a UK University Hospital asked MUTU to help provide digital care and guidance to patients that were not able to be seen in person due to the pandemic. 

MUTU Clinical TrialThe MUTU Clinical Trial provided the 12 module MUTU System program to women who had been patients of the Pelvic and Maternal Health Team in pregnancy or postnatally. These women ranged in symptoms they were dealing with but most participants presented with diastasis of the rectus abdominus muscles (DRAM). 

110 expectant and new mothers participated in the MUTU Clinical Trial doing the MUTU program, between April-July 2020. The main focus of this trial was to assess the efficiency and effectiveness of digital postpartum care during and after the pandemic. The trial also ensured maternity patients received safe and credible pelvic health solutions and postpartum rehabilitation during the lockdown.

Top Results of MUTU Clinical Trial

96% of women saw improvement in bladder weakness

91% saw diastasis recti improvement

95% felt better about their body function

76% of women claimed to feel physically stronger

59% more self-confident and mentally stronger

A barrier that is often noted by physiotherapists is patients not actually doing the exercises outside of appointments- which compliance to actually ‘doing the exercises’ is crucial for success and full recovery. The University Hospital physiotherapy team were especially impressed with the women’s commitment to the at-home program during the MUTU Clinical Trial. They were also impressed with the clear instruction and user experience of MUTU. The engaged private community with expert assistance when participants needed it also had a positive impact.

More Notable Findings: MUTU Clinical Trial 2

100% of the respondents who spoke about prolapse symptoms saw an improvement by Week 3 of using MUTU System

100% of respondents who couldn’t locate their pelvic floor muscles prior to starting MUTU, could do so by week 3

Of the respondents who experienced pain or discomfort during sexual intercourse, 90% had experienced an improvement by Week 9, and 93% by Week 12.

It was found as well that the number of women experiencing painful intercourse, or prolapse symptoms were higher at the early stage of motherhood than expected. Usually, these women are not referred until much later, or they don’t come forward at all.

This is important to note because by acknowledging and tackling these distressing postpartum symptoms earlier with MUTU, demand on University Hospital resources were reduced and women received needed care earlier than they would have.

Lucy Eggleton, Lead WH Physiotherapist said:

“The results from the trial have been really interesting as, although the women were referred predominantly with diastasis being their main postnatal symptom, many were also experiencing other distressing postnatal symptoms such as pelvic organ prolapse, incontinence or pain on resuming intercourse.

It has been great to see that so many women have found relief from these symptoms through participating in the MUTU program alongside physiotherapy and moving forwards this will be a program we are happy to support and refer our patients onto.”

“…In a time of such difficulty when so many new mothers have felt isolated and unsupported, it was brilliant to be able to team up with Wendy and the MUTU System to be able to run a clinical trial… We have been so impressed with the feedback and results, seeing women restored back to full health and function.

MUTU is approved by ORCHA and NHS Digital for the NHS Apps Library. For more clinical and survey evidence for MUTU System, see our MUTU Evidence or full Medical Reference pages.

For medical professionals, hospitals, and Trusts interested in more detailed results and to discuss MUTU in your practice, setting or Trust, please contact MUTU CEO, Wendy Powell. Wendy is a 2021 shortlisted NHS Innovation Accelerator Fellow and NICE stakeholder.